21718-02-5Relevant academic research and scientific papers
INHIBITOR COMPOUNDS
-
Page/Page column 63; 158-159, (2021/01/29)
The disclosure relates to heterocyclic compounds and methods for their preparation. The disclosure provides compounds that may have beneficial therapeutic activity in the treatment of a disease or condition mediated by excessive or otherwise undesirable Des1 and/or fibrotic activity.
Synthesis and evaluation of 1,3,4-oxadiazole derivatives for development as broad-spectrum antibiotics
Tresse, Cédric,Radigue, Richard,Gomes Von Borowski, Rafael,Thepaut, Marion,Hanh Le, Hong,Demay, Fanny,Georgeault, Sylvie,Dhalluin, Anne,Trautwetter, Annie,Ermel, Gwennola,Blanco, Carlos,van de Weghe, Pierre,Jean, Micka?l,Giard, Jean-Christophe,Gillet, Reynald
, (2019/09/18)
The reality and intensity of antibiotic resistance in pathogenic bacteria calls for the rapid development of new antimicrobial drugs. In bacteria, trans-translation is the primary quality control mechanism for rescuing ribosomes arrested during translation. Because trans-translation is absent in eukaryotes but necessary to avoid ribosomal stalling and therefore essential for bacterial survival, it is a promising target either for novel antibiotics or for improving the activities of the protein synthesis inhibitors already in use. Oxadiazole derivatives display strong bactericidal activity against a large number of bacteria, but their effects on trans-translation were recently questioned. In this work, a series of new 1,3,4-oxadiazole derivatives and analogs were synthesized and assessed for their efficiency as antimicrobial agents against a wide range of gram-positive and gram-negative pathogenic strains. Despite the strong antimicrobial activity observed in these molecules, it turns out that they do not target trans-translation in vivo, but they definitely act on other cellular pathways.
